Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908582 · ClinicalTrials.gov registry record · Phase 1
A Study of Evacetrapib and Rifampin in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01908582 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 26 participants.
The verdict
NCT01908582, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine how much evacetrapib gets into the blood stream and how long it takes the body to get rid of it when given with rifampin. The safety and tolerability of the two drugs, given together, will also be evaluated. The study will also look at blood cholesterol levels and levels of a hormone called cortisol before and after taking rifampin. Information about any side effects that may occur will also be collected. For each participant, this study will include 2 periods in fixed order. The study will last approximately 29 days.
Interventions
- DRUG Rifampin
- DRUG Evacetrapib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01908582
The ClinicalTrials.gov registry entry for NCT01908582 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifampin is the first listed.
NCT01908582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01908582 about?
NCT01908582 is a clinical study titled "A Study of Evacetrapib and Rifampin in Healthy Participants". The main purpose of this study is to determine how much evacetrapib gets into the blood stream and how long it takes the body to get rid of it when given with rifampin. The safety and tolerability of the two drugs, given together, will also be evaluated. The study will also look at blood cholesterol...
What is the current status of trial NCT01908582?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-07. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01908582?
The interventions under investigation include: Rifampin (DRUG), Evacetrapib (DRUG).
Who is sponsoring clinical trial NCT01908582?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.